Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
30.05. | Ikena Oncology, Inc. - S-4/A, Registration of securities, business combinations | 1 | SEC Filings | ||
IKENA ONCOLOGY Aktie jetzt für 0€ handeln | |||||
20.05. | Ikena Oncology, Inc. - S-4/A, Registration of securities, business combinations | 2 | SEC Filings | ||
08.05. | Ikena Oncology, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
07.05. | Ikena Oncology, Inc. - S-4/A, Registration of securities, business combinations | 4 | SEC Filings | ||
21.04. | Ikena Oncology, Inc. - S-4/A, Registration of securities, business combinations | 2 | SEC Filings | ||
18.03. | Ikena Oncology, Inc. - S-4, Registration of securities, business combinations | 4 | SEC Filings | ||
06.03. | Ikena Oncology, Inc. - 10-K, Annual Report | - | SEC Filings | ||
23.12.24 | Ikena Oncology and Inmagene Biopharmaceuticals announces merger | 14 | Seeking Alpha | ||
23.12.24 | Ikena Oncology, Inc.: Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement | 186 | GlobeNewswire (Europe) | Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function The transaction... ► Artikel lesen | |
23.12.24 | Ikena Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
07.11.24 | Ikena Oncology, Inc.: Ikena Oncology Reports Third Quarter 2024 Financial Results | 217 | GlobeNewswire (Europe) | BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, "Ikena," "Company") today announced financial results for the third quarter ended September 30, 2024, and provided an... ► Artikel lesen | |
08.08.24 | Ikena Oncology, Inc.: Ikena Oncology Reports Second Quarter 2024 Financial Results | 185 | GlobeNewswire (Europe) | BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, "Ikena," "Company") today announced financial results for the second quarter ended June 30, 2024, and provided an update... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 7,060 | +0,94 % | Evotec Aktie: Ohne Übernahme sieht es schlecht aus! Auf diese Kursmarke kommt es an! | © Foto: Finanznachrichten (Symbolbild)Zwischen Kursrakete mit Übernahmefantasie und Korrekturmodus Richtung Süden. Der Biotech-Titel aus Hamburg liefert seit Wochen ein Wechselbad der Gefühle. Kann... ► Artikel lesen | |
BIOGEN | 116,70 | -0,09 % | DAX tritt auf der Stelle - Nvidia & Biogen mit Überraschung! Gold, EUR & Aktien im Chartcheck | ||
PALATIN TECHNOLOGIES | 0,088 | 0,00 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
MAINZ BIOMED | 2,775 | -100,00 % | MAINZ BIOMED N.V. - 6-K, Report of foreign issuer | ||
VIKING THERAPEUTICS | 24,220 | -0,78 % | Viking Therapeutics auf Jefferies-Konferenz: Vielversprechendes Abnehm-Medikament | ||
TREVENA | 0,153 | 0,00 % | Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc. ... | NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the Class A Ordinary Shares, unit, and warrant of Patria Latin American Opportunity Acquisition... ► Artikel lesen | |
CELLECTAR BIOSCIENCES | 0,322 | +0,62 % | Cellectar +147%: Ich nehme die Gewinne mit! | Meine Spekulation geht auf: Cellectar Biosciences (WKN: A3DQSD) knallt heute in der Spitze um bis zu +147% durch die Decke, nachdem ich im März ein großes Comeback der Aktie in Aussicht gestellt hatte.... ► Artikel lesen | |
GALAPAGOS NV | 24,420 | +0,25 % | Galapagos NV: Galapagos Creates New Subscription Right Plan | Mechelen, Belgium; May 27, 2025, 22:30 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 925,000 subscription rights under a new... ► Artikel lesen | |
CENTOGENE | 0,120 | 0,00 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
SENSEI BIOTHERAPEUTICS | 0,310 | -0,32 % | H.C. Wainwright stuft Sensei Biotherapeutics-Aktie mit "Kaufen" ein | ||
COHERUS ONCOLOGY | 0,738 | +2,08 % | Coherus BioSciences, Inc. (CHRS): A Bull Case Theory | ||
AC IMMUNE | 1,756 | -1,46 % | AC Immune SA: AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update | AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseasesPositive... ► Artikel lesen | |
CYTOMX THERAPEUTICS | 2,338 | +0,34 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA (pembrolizumab) in Patients with Metastatic Melanoma | SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the... ► Artikel lesen | |
CYTOKINETICS | 28,600 | +0,70 % | Cytokinetics auf der Jefferies-Konferenz: Marktexpansion für Aficamten | ||
PERSONALIS | 4,682 | +2,32 % | Personalis enthüllt: ctDNA-Test sagt Rückfall bei Gebärmutterhalskrebs voraus |